Kezar Life Sciences, Inc. has 10 Schedule 13D or 13G filings on record since 2025-09-08. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Stonepine Capital Management, LLC | 2.1% | 156,179 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Avidity Partners Management LP | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| BML Investment Partners, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-12 | 2026-05-11 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13D/A, 2026-05-13 | 2026-05-11 |
| Baselake Partners, LP | 0% | 0 | SCHEDULE 13G/A, 2026-05-28 | 2026-05-11 |
Purpose of Transaction (Item 4)
Tang Capital Management, LLC
Item 4 of the Original Schedule 13D is hereby amended to add the following: Closing of the Merger: On May 11, 2026, the Issuer completed its merger with Aurinia Pharma U.S., Inc. ("Parent") and Parent's wholly-owned subsidiary, Aurinia Merger Sub, Inc. ("Merger Sub") pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, on May 11, 2026, each issued and outstanding share of the Issuer's Common Stock was cancelled.Item 4 of the SCHEDULE 13D/A filed 2026-05-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-08 | Stonepine Capital Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-11-14 | Avidity Partners Management LP | 0% | SCHEDULE 13G/A |
| 2026-02-09 | BML Investment Partners, L.P. | 9.8% | SCHEDULE 13G/A |
| 2026-02-13 | Stonepine Capital Management, LLC | 2.1% | SCHEDULE 13G/A |
| 2026-04-01 | Tang Capital Management, LLC | 9% | SCHEDULE 13D/A |
| 2026-04-06 | Baselake Partners, LP | 5.3% | SCHEDULE 13G |
| 2026-05-12 | BML Investment Partners, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-12 | Baselake Partners, LP | 0% | SCHEDULE 13G/A |
| 2026-05-13 | Tang Capital Management, LLC | 0% | SCHEDULE 13D/A |
| 2026-05-28 | Baselake Partners, LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Kezar Life Sciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.